Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads In Myelodysplastic Syndrome

Myelodysplastic Syndrome for September/October 2019

Genetic analysis highlights value of germline variants in MDS, AML,

More must reads

Myelodysplastic Syndrome for May/June 2019

Antibody targeting ‘do not eat me’ signals is active in AML, MDS,

Combo proves most effective in HMA-naive, higher-risk MDS,

More abnormal cells linked to poorer ASCT outcomes in MDS,

More must reads

Myelodysplastic Syndrome for March/April 2019

Model inspired by Netflix, Amazon may help guide MDS treatment,

Sorafenib plus GCLAM yielded 83% complete response rate in AML, MDS,

More must reads

Myelodysplastic Syndrome for September/October 2018

Gene sequencing bone marrow in myelodysplastic syndrome, Duncavage EJ et al. N Engl J Med 2018;379:1028-41.
More must reads

Myelodysplastic Syndrome for July/August 2018

JAK1/2 inhibitors tied to increased B-cell lymphoma risk, Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.
More must reads

Pages